Ascendiant Capital Markets Estimates VVOS Q1 Earnings

Vivos Therapeutics, Inc. (NASDAQ:VVOS) – Ascendiant Capital Markets issued their Q1 2027 earnings per share (EPS) estimates for shares of Vivos Therapeutics in a research note issued to investors on Thursday, June 4th. Ascendiant Capital Markets analyst L. Ward forecasts that the company will post earnings per share of ($0.57) for the quarter. Ascendiant Capital Markets currently has a “Buy” rating and a $3.10 target price on the stock. The consensus estimate for Vivos Therapeutics’ current full-year earnings is ($1.39) per share. Ascendiant Capital Markets also issued estimates for Vivos Therapeutics’ Q2 2027 earnings at ($0.55) EPS, Q3 2027 earnings at ($0.53) EPS and Q4 2027 earnings at ($0.53) EPS.

VVOS has been the subject of several other research reports. HC Wainwright cut their target price on Vivos Therapeutics from $7.00 to $2.50 and set a “buy” rating for the company in a research report on Friday, April 17th. Weiss Ratings restated a “sell (e+)” rating on shares of Vivos Therapeutics in a research report on Monday, April 20th. Two research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $2.80.

Vivos Therapeutics Price Performance

Vivos Therapeutics stock opened at $0.70 on Wednesday. The company has a debt-to-equity ratio of 3.31, a current ratio of 0.27 and a quick ratio of 0.27. The company has a market capitalization of $9.73 million, a PE ratio of -0.33 and a beta of 6.10. Vivos Therapeutics has a one year low of $0.55 and a one year high of $7.95. The business has a 50 day simple moving average of $0.88 and a 200 day simple moving average of $1.47.

Vivos Therapeutics (NASDAQ:VVOS) last posted its earnings results on Wednesday, May 20th. The company reported ($0.52) EPS for the quarter, missing the consensus estimate of ($0.45) by ($0.07). The company had revenue of $5.14 million for the quarter, compared to the consensus estimate of $4.35 million. Vivos Therapeutics had a negative return on equity of 2,325.64% and a negative net margin of 127.70%.

Insider Transactions at Vivos Therapeutics

In other Vivos Therapeutics news, major shareholder Michael C. Skaff acquired 1,353,625 shares of the business’s stock in a transaction on Tuesday, March 31st. The stock was purchased at an average price of $1.34 per share, for a total transaction of $1,813,857.50. Following the transaction, the insider owned 1,353,625 shares in the company, valued at $1,813,857.50. This trade represents a ∞ increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 2.10% of the company’s stock.

Institutional Investors Weigh In On Vivos Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the company. Acorn Wealth Advisors LLC acquired a new stake in shares of Vivos Therapeutics during the fourth quarter worth $30,000. XTX Topco Ltd acquired a new position in Vivos Therapeutics in the second quarter valued at about $65,000. Sequoia Financial Advisors LLC acquired a new position in Vivos Therapeutics in the first quarter valued at about $28,000. B. Riley Wealth Advisors Inc. acquired a new position in Vivos Therapeutics in the second quarter valued at about $220,000. Finally, DRW Securities LLC grew its stake in Vivos Therapeutics by 179.5% in the fourth quarter. DRW Securities LLC now owns 115,907 shares of the company’s stock valued at $235,000 after acquiring an additional 74,441 shares during the period. Institutional investors own 26.35% of the company’s stock.

About Vivos Therapeutics

Vivos Therapeutics, Inc is a medical technology company focused on the development and commercialization of oral appliance therapy for the treatment of obstructive sleep apnea (OSA) and other airway-related disorders. The company’s proprietary Vivos System integrates clinical diagnostic protocols, three-dimensional imaging, and custom-designed dental appliances to address mild to moderate forms of sleep-disordered breathing through non-surgical, non-invasive means.

The Vivos System comprises a range of custom oral devices, digital workflow tools, and a structured treatment protocol.